| Zacks Company Profile for Nurix Therapeutics, Inc. (NRIX : NSDQ) |
|
|
| |
| • Company Description |
| Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.
Number of Employees: 286 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $19.07 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,812,872 shares |
| Shares Outstanding: 76.88 (millions) |
| Market Capitalization: $1,466.16 (millions) |
| Beta: 1.87 |
| 52 Week High: $22.50 |
| 52 Week Low: $8.18 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
53.42% |
51.40% |
| 12 Week |
112.60% |
106.51% |
| Year To Date |
1.22% |
-13.73% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
1700 OWENS STREET SUITE 205
-
SAN FRANCISCO,CA 94158
USA |
ph: 415-660-5320
fax: - |
ir@nurixtx.com |
http://www.nurixtx.com |
|
|
| |
| • General Corporate Information |
Officers
Arthur T. Sands - Chief Executive Officer; President and Director
Julia P. Gregory - Chairman
Hans van Houte - Chief Financial Officer
Anil Kapur - Director
Lori A. Kunkel - Director
|
|
Peer Information
Nurix Therapeutics, Inc. (CORR.)
Nurix Therapeutics, Inc. (RSPI)
Nurix Therapeutics, Inc. (CGXP)
Nurix Therapeutics, Inc. (BGEN)
Nurix Therapeutics, Inc. (GTBP)
Nurix Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 67080M103
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: November
Last Reported Quarter: 08/01/25
Next Expected EPS Date: 01/27/26
|
|
Share - Related Items
Shares Outstanding: 76.88
Most Recent Split Date: (:1)
Beta: 1.87
Market Capitalization: $1,466.16 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.80 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-3.10 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 8.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 01/27/26 |
|
|
|
| |
